In a bold White House address, President Trump announced sweeping deals with pharma powerhouses, branding them the biggest price cuts on prescription drugs ever. This initiative targets the outrageous costs Americans have endured, aligning U.S. prices with the cheapest global rates.
Pivotal in the lineup, Regeneron agreed to ‘most favored nation’ terms, vowing unprecedented reductions. Trump boasted that 17 dominant companies, representing 80% of branded drugs, will now offer Americans the world’s lowest prices.
The longstanding gripe? U.S. consumers have paid top dollar for decades, funding cheaper drugs abroad. HHS Secretary Robert F. Kennedy Jr. slammed this as systemic plunder, with America—4.2% of global population—delivering 75% of pharma profits.
Medicare chief Mehmet Oz painted a stark picture: every third American forgoes vital meds due to expense. Concrete examples: cholesterol treatment prices halved from $537 to $225; weight-loss drugs plummet from $1,350 monthly to $199.
Regeneron CEO Leonard Schleifer embraced the shift, not under duress but as a smart evolution. Adding innovation, they launched a first-of-its-kind gene therapy for congenital deafness, free for qualifying kids short-term. George Yancopoulos described how young Travis now hears his mom’s voice, a medical miracle.
Sierra Smith, mother of a treated two-year-old, gushed over the ‘incredible’ transformation. Commerce Secretary Howard Lutnick linked it to jobs, forecasting $448 billion in U.S. production repatriation. With 86% market coverage and talks ongoing, Trump’s push could redefine affordable medicine.
